Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice: Implications for therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 9, 2011, Pages 1164-1175

  Nakanishi, Kaori ^a   Takeda, Yoshito ^a   Tetsumoto, Satoshi ^a   Iwasaki, Takeo ^a   Tsujino, Kazuyuki ^a   Kuhara, Hanako ^a   Jin, Yingji ^a   Nagatomo, Izumi ^a   Kida, Hiroshi ^a   Goya, Sho ^a   Kijima, Takashi ^a   Maeda, Norikazu ^b   Funahashi, Tohru ^b   Shimomura, Iichiro ^b   Tachibana, Isao ^a   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Chronic obstructive pulmonary disease; Comorbidities; Endothelial apoptosis; Systemic inflammation

Indexed keywords

ADIPONECTIN; CASPASE 3; CD31 ANTIGEN; ELASTASE; VASCULOTROPIN RECEPTOR 2;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATROPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; EMPHYSEMA; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT ATROPHY; HISTOPATHOLOGY; HYPOADIPONECTINEMIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG ALVEOLUS; LUNG COMPLIANCE; LUNG FUNCTION TEST; LUNG LAVAGE; MOUSE; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT REDUCTION;

ADIPONECTIN; ANIMALS; ANTIGENS, CD31; APOPTOSIS; CASPASE 3; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; LUNG COMPLIANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPOROSIS; PANCREATIC ELASTASE; PHENOTYPE; PULMONARY ALVEOLI; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WEIGHT LOSS;

EID: 79955519064     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201007-1091OC     Document Type: Article

References (54)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243.
2. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-212.
3. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease [review]. Eur Respir J 2003;21:347-360. (Pubitemid 36204553)
4. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-415.
5. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease [review]. Proc Am Thorac Soc 2008;5:549-555. (Pubitemid 351669185)
6. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519. (Pubitemid 36378490)
7. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity [review]. Nat Rev Immunol 2006;6:772-783. (Pubitemid 44453463)
8. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. J Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome [review]. Clin Investig 2006;116:1784-1792. (Pubitemid 44033298)
9. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-1732. (Pubitemid 30661055)
10. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors [review]. Endocr Rev 2005;26:439-451.
11. Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T, Ouchi N, Ohashi K, Kihara S, Funahashi T, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005;45:1094-1100. (Pubitemid 40770311)
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83. (Pubitemid 29299050)
13. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, Matsuzawa Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27-e31.
14. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731-737. (Pubitemid 34778727)
15. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-339. (Pubitemid 46376688)
16. Goldstein BJ, Scalia RG,Ma XL. Protective vascular and myocardial effects of adiponectin [review]. Nat Clin Pract Cardiovasc Med 2009;6:27-35.
17. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-799.
18. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007;87:1047-1082. (Pubitemid 47084676)
19. Takeda Y, He P, Tachibana I, Zhou B, Miyado K, Kaneko H, Suzuki M, Minami S, Iwasaki T, Goya S, et al. Double deficiency of tetraspanins CD9 and CD81 alters cell motility and protease production of macrophages and causes chronic obstructive pulmonary disease-like phenotype in mice. J Biol Chem 2008;283:26089-26097.
20. Kawakami M, Matsuo Y, Yoshiura K, Nagase T, Yamashita N. Sequential and quantitative analysis of a murine model of elastaseinduced emphysema. Biol Pharm Bull 2008;31:1434-1438. (Pubitemid 351930664)
21. Grydeland TB, Dirksen A, Coxson HO, Eagan TM, Thorsen E, Pillai SG, Sharma S, Eide GE, Gulsvik A, Bakke PS. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med 2010;181:353-359.
22. Summer R, Little FF, Ouchi N, Takemura Y, Aprahamian T, Dwyer D, Fitzsimmons K, Suki B, Parameswaran H, Fine A, et al. Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am J Physiol Lung Cell Mol Physiol 2008; 294:L1035-L1042.
23. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms [review]. Eur Respir J 2003;22:672-688. (Pubitemid 37258549)
24. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease [review]. Am J Respir Cell Mol Biol 2009;41:631-638.
25. Devaraj S, Torok N, Dasu MR, Samols D, Jialal I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 2008;28:1368-1374.
26. Kurosaki H, Ishii T, Motohashi N, Motegi T, Yamada K, Kudoh S, Jones RC, Kida K. Extent of emphysema on HRCT affects loss of fat-free mass and fat mass in COPD. Intern Med 2009;48:41-48.
27. Summer R, Fiack CA, Ikeda Y, Sato K, Dwyer D, Ouchi N, Fine A, Farber HW, Walsh K. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol 2009;297:L432-L438.
28. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 2003;28:555-562. (Pubitemid 36543402)
29. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-1319.
30. Tuder RM, Yoshida T, Fijalkowka I, Biswal S, Petrache I. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema [review]. Proc Am Thorac Soc 2006;3:673-679. (Pubitemid 44788223)
31. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung [review]. Am J Physiol Lung Cell Mol Physiol 2006; 290:L209-L221.
32. Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, Raher MJ, Kihara S, Bloch KD, Libby P, Luster AD. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 2009;41:397-406.
33. Miller M, Cho JY, Pham A, Ramsdell J, Broide DH. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol 2009;182:684-691.
34. Chiarugi P, Fiaschi T. Adiponectin in health and diseases: from metabolic syndrome to tissue regeneration [review]. Expert Opin Ther Targets 2010;14:193-206.
35. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, Makino H. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006;33:1545-1552. (Pubitemid 44168825)
36. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762. (Pubitemid 41372115)
37. Abbasi F, Farin HM, Lamendola C, McLaughlin T, Schwartz EA, Reaven GM, Reaven PD. The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers. J Clin Endocrinol Metab 2006;91:5002-5007. (Pubitemid 44917341)
38. Tomoda K, Yoshikawa M, Itoh T, Tamaki S, Fukuoka A, Komeda K, Kimura H. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 2007;132:135-140. (Pubitemid 47068213)
39. Chan KH, Yeung SC, Yao TJ, Ip MS, Cheung AH, Chan-Yeung MM, Mak JC; COPD Study Group of the Hong Kong Thoracic Society. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2010;14:1193-1200.
40. Krommidas G, Kostikas K, Papatheodorou G, Koutsokera A, Gourgoulianis KI, Roussos C, Koulouris NG, Loukides S. Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. Respir Med 2010;104:40-46.
41. Shi W, Bellusci S, Warburton D. Lung development and adult lung diseases [review]. Chest 2007;132:651-656. (Pubitemid 47282400)
42. Tang K, Rossiter HB, Wagner PD, Breen EC. Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice. J Appl Physiol 2004;97:1559-1566. (Pubitemid 39299378)
43. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001;163:737-744. (Pubitemid 32230838)
44. Shibata R, Skurk C, Ouchi N, Galasso G, Kondo K, Ohashi T, Shimano M, Kihara S, Murohara T, Walsh K. Adiponectin promotes endothelial progenitor cell number and function. FEBS Lett 2008;582:1607-1612.
45. Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology [review]. Arterioscler Thromb Vasc Biol 2003;23:953-964. (Pubitemid 36713547)
46. DeLisser HM, Helmke BP, Cao G, Egan PM, Taichman D, Fehrenbach M, Zaman A, Cui Z, Mohan GS, Baldwin HS, et al. Loss of PECAM-1 function impairs alveolarization. J Biol Chem 2006;281:8724-8731. (Pubitemid 43847977)
47. Palange P, Testa U, Huertas A, Calabrò L, Antonucci R, Petrucci E, Pelosi E, Pasquini L, Satta A, Morici G, et al. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J 2006;27:529-541. (Pubitemid 43372527)
48. Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease [review]. Chest 2006;129:1673-1682. (Pubitemid 43895000)
49. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S, Walsh K. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007;117:375-386. (Pubitemid 46203966)
50. Otabe S, Yuan X, Fukutani T, Wada N, Hashinaga T, Nakayama H, Hirota N, Kojima M, Yamada K. Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocrinol Metab 2007;293:E210-E218. (Pubitemid 47105934)
51. Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, Kozono H, Takamoto I, Okamoto S, Shiuchi T, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007;6:55-68. (Pubitemid 47007437)
52. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99:196-208. (Pubitemid 44297964)
53. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging [review]. Chest 2009;135:173-180.
54. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensinconverting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-2560. (Pubitemid 43866389)